期刊文献+

苯扎贝特引起横纹肌溶解的回顾性分析 被引量:4

下载PDF
导出
摘要 目的分析苯扎贝特致横纹肌溶解的相关性,以利论药合理运用。方法计算机检索Medline、Embase、中国期刊全文数据库、万方数据库,查阅所有与苯扎贝特致横纹肌溶解的相关文献。结果共检索到12篇文献,其中中文文献4篇,外文文献8篇。结论即使单独使用贝特类药物,也应警惕可能引起的横纹肌溶解。
作者 李明山 徐鹏
出处 《中国药业》 CAS 2011年第16期70-71,共2页 China Pharmaceuticals
  • 相关文献

参考文献12

  • 1鄢琳,曹立亚,雷建军,兰奋,李静,肖爱丽,邹燕,白雪,章渝,王超,张力文,李幼平.9种调血脂药物有效性及安全性评价[J].中国循证医学杂志,2005,5(1):8-21. 被引量:51
  • 2楚修林,范俊德,王艳霞,贾鹏宇.苯扎贝特致横纹肌溶解症、急性肾衰竭、心肌损伤1例[J].新医学,2008,39(4):270-270. 被引量:6
  • 3孙霞,吴葆杰,张岫美.调血脂药物与肌病、横纹肌溶解症[J].中国药理学通报,2003,19(2):130-133. 被引量:48
  • 4张亚琴,郭萍.药物致横纹肌溶解症的综合治疗[J].西北药学杂志,2006,21(4):179-179. 被引量:1
  • 5Eleanora Plotkin, Jacques Bernheim. Influenza vaccine - a possible trigger of rhabdomyolysis induced acute renal failure due to the combined use of eerivastatin and bezafibrate [J ]. J Nephrol Dial Transplant, 2000, 15:740 - 741.
  • 6E Kanterewicz, R Sanmarti. Bezafibrate induced rhabdomyolysis[J] . Ann Rheum Dis, 1992,51:536 - 538.
  • 7Chrisafghi T, Terrovitou. Acute Rhabdomyolysis after Bezafibrate Re - Expo- sure[J]. Nephron, 1998,78:336 - 337.
  • 8Saito Makoto, Okamoto Hiroshi. A Case with Aggravated Renal Failure Due to Rhabdomyolysis after Combined Administration of Simvastatin and Bezafi- brate of which Renal Function was Subsequently Improved by Discontinuance of these Agents [ J ]. Japanese Journal of Hospital Pharmacy, 2000,26 : 659 - 664.
  • 9Inoue M, Jimi T, Machida H, et al. Bezafibrate myopathy in two patients with chronic renal failure [J ]. Rinsho Shinkeigaku, 1992,32:725 - 728.
  • 10Jianyong Wu, Yan Song. Rhabdomyolysis associated with fibrate therapy:re- view of 76 published cases and a new case report [J]. European Journal of Clinical Pharmacology,2009,65 : 1 169 - 1 174.

二级参考文献100

  • 1金立仁,陈万春,胡伟国,包玉倩.阿西莫司的降脂效应[J].新药与临床,1993,12(5):297-298. 被引量:7
  • 2胡雪红.降脂药致肌痛二例[J].临床误诊误治,2005,18(4):295-295. 被引量:11
  • 3陈斌,韩琴琴,陈曙霞,梅尚义,胡义桥,陈淑良.吉非贝齐与非诺贝特降脂疗效比较[J].新药与临床,1995,14(2):77-79. 被引量:12
  • 4何玲 刘国卿 见:王永铭 苏定冯主编.P-糖蛋白调节的药物转运与ATPase活性[A].见:王永铭,苏定冯主编.药理学进展[C].北京:科学出版社,2000.61~8.
  • 5王家良.循证医学(第1版)[M].北京:人民卫生出版社,2001.5-50.
  • 6David Moher, Kenneth F Schulz, Douglas G Altman, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of paralleo-group randomized trials [J]. TheLancet, 2001; 357(4): 1 191-1 194
  • 7Stalenhoef AF, Lansberg PJ, Kroon AA, Kortmann B, De Haan AF,Stuyt PM, Kastelein JJ. Treatment of primary hypercholesterolaemia.Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study [ J ]. J Intem Med,1993; 234(1): 77-82
  • 8The European Study Group. Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia ( multicountry comparative study) [J ]. Am J Cardiol, 1992; 70 ( 15 ): 1281 - 1 286
  • 9Lambrecht LJ, Malini PL. Efficacy and tolerability of simvastatin 20mg vs pravastatin 20 mg in patients with primary hypercholesterolemia.European Study Group[J]. Acta Cardiol, 1993; 48(6): 541 -554
  • 10Steinhagen-Thiessen E. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group [J ].Cardiology, 1994; 85(3-4): 244-254

共引文献100

同被引文献14

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部